Abstract
Cathepsin S (CatS) is one of the 11 cysteine protease cathepsins which are expressed predominantly in antigen presenting cells (APC) namely B cells, macrophages and dendritic cells. CatS has been implicated in a wide range of diseases such as rheumatoid arthritis, multiple sclerosis, neuropathic pain and allergic disorders. In the present study, pharmacophore mapping studies followed by 3D QSAR analysis was undertaken for a large set of 161 molecules reported to be non-covalent binding and non-peptidic inhibitors of CatS. The activity range (IC50) of these compounds was between 2 picomolar to 100 nanomolar. A five point pharmacophore model with three hydrogen bond acceptors (A), one hydrogen bond donor (D) and one hydrophobic (H) group as pharmacophoric features was developed. The generated model showed reasonable predictive power, with a correlation coefficient Q2 of 0.607. The model was further confirmed by an external test-set validation that showed statistically significant parameters r2 value of 0.840with the R2p value of 0.812 and r2m value of 0.530. Validated model was then used to identify six diverse non-peptidic scaffolds from a commercial structure database by the analyses of parameters such as pharmacophore fitness, docking score, interacting amino acids and ADME properties to achieve prototypical lead compounds.
Keywords: Cathepsin S, pharmacophore modeling, 3D QSAR, virtual screening, pharmacokinetics.
Current Medicinal Chemistry
Title:Pharmacophore-Based 3DQSAR and Molecular Docking Studies to Identify New Non-Peptidic Inhibitors of Cathepsin S
Volume: 21 Issue: 16
Author(s): M.B. Battu, A.M. Chandra, D. Sriram and P. Yogeeswari
Affiliation:
Keywords: Cathepsin S, pharmacophore modeling, 3D QSAR, virtual screening, pharmacokinetics.
Abstract: Cathepsin S (CatS) is one of the 11 cysteine protease cathepsins which are expressed predominantly in antigen presenting cells (APC) namely B cells, macrophages and dendritic cells. CatS has been implicated in a wide range of diseases such as rheumatoid arthritis, multiple sclerosis, neuropathic pain and allergic disorders. In the present study, pharmacophore mapping studies followed by 3D QSAR analysis was undertaken for a large set of 161 molecules reported to be non-covalent binding and non-peptidic inhibitors of CatS. The activity range (IC50) of these compounds was between 2 picomolar to 100 nanomolar. A five point pharmacophore model with three hydrogen bond acceptors (A), one hydrogen bond donor (D) and one hydrophobic (H) group as pharmacophoric features was developed. The generated model showed reasonable predictive power, with a correlation coefficient Q2 of 0.607. The model was further confirmed by an external test-set validation that showed statistically significant parameters r2 value of 0.840with the R2p value of 0.812 and r2m value of 0.530. Validated model was then used to identify six diverse non-peptidic scaffolds from a commercial structure database by the analyses of parameters such as pharmacophore fitness, docking score, interacting amino acids and ADME properties to achieve prototypical lead compounds.
Export Options
About this article
Cite this article as:
Battu M.B., Chandra A.M., Sriram D. and Yogeeswari P., Pharmacophore-Based 3DQSAR and Molecular Docking Studies to Identify New Non-Peptidic Inhibitors of Cathepsin S, Current Medicinal Chemistry 2014; 21 (16) . https://dx.doi.org/10.2174/09298673113206660275
DOI https://dx.doi.org/10.2174/09298673113206660275 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Somatostatin Involvement in Rheumatoid Arthritis
Current Rheumatology Reviews Selenoproteins and their Role in Oxidative Stress and Inflammation
Current Chemical Biology New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews The Role of Chemokines in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Advances in Electrospinning of Nanofibers and their Biomedical Applications
Current Tissue Engineering (Discontinued) Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Current Topics in Medicinal Chemistry Targeting the Prokineticin System to Control Chronic Pain and Inflammation
Current Medicinal Chemistry Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design Treatment of Stage I and II Scapholunate Advanced Collapse (SLAC) Wrist
Current Rheumatology Reviews COX-2: Friend or Foe?
Current Pharmaceutical Design IL-22 and Its Receptors, New Players in the Inflammatory Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery NF-κB Signaling: Multiple Angles to Target OA
Current Drug Targets Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives
Current Medicinal Chemistry